Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $86.40 USD
Change Today -0.25 / -0.29%
Volume 1.6M
NVS On Other Exchanges
New York
SIX Swiss Ex
SIX Swiss Ex
As of 8:04 PM 11/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056


Phone: 41 61 324 11 11


seases, such as glaucoma and macular degeneration. In 2014, the company entered into an agreement with Google [x] to license its ‘smart lens’ technology with the potential to address ocular conditions. In 2014, the company acquired WaveTec Vision. The acquisition provided the company with the ORA System, a commercialized intra-operative guidance system for cataract surgeons implanting intraocular lenses (IOLs). In 2012, the company gained rights from ThromboGenics to commercialize Jetrea (ocriplasmin) intravitreal injection outside the U.S. Jetrea is a pharmacological treatment for vitreomacular traction, including macular hole, in Europe. In 2012, the company acquired Endure Medical Systems. The acquisition enabled it to enter into the ophthalmic microscopy field through the addition of the LuxOR microscope, which has applications for both cataract, as well as vitreoretinal surgeries. Products Surgical The Alcon division offers ophthalmic surgical equipment, instruments, disposable products and intraocular lenses for surgical procedures that address cataracts, vitreoretinal conditions, glaucoma and refractive errors. The company’s surgical portfolio includes the Cataract Refractive Suite by Alcon, a suite of equipment to help plan and perform some of the most challenging steps of cataract surgery with automation and precision. It consists of the Centurion vision system phacoemulsification technology platform; the LenSx laser, a femtosecond laser for increased precision and reproducibility for the corneal incision, capsulorhexis and lens fragmentation steps of the procedure; the Verion image guided system, an ocular surgical planning, imaging and guidance technology; the ORA System, an intra-operative guidance system for IOL implantation during cataract surgery; and the LuxOR LX3 surgical microscope for greater visualization during surgery. The portfolio also includes the Infiniti vision system to perform cataract surgeries, which is the phacoemulsification platform introduced prior to the Centurion vision system, the Constellation vision system for retinal operations, and the WaveLight refractive suite for refractive procedures and Lasik treatments. The company also offers the AcrySof family of intraocular lenses (IOLs) to treat cataracts, including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. In addition, the company provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery. Ophthalmic Pharmaceuticals The Alcon division's Ophthalmic Pharmaceuticals franchise develops and markets a range of pharmaceuticals to treat chronic and acute conditions of the eye, including glaucoma, elevated intraocular pressure (associated with glaucoma), eye infection and inflammation, eye allergies, dry eye and retinal diseases. Ophthalmic Pharmaceuticals also oversees the line of professionally driven over-the-counter brands that include artificial tears and ocular vitamins. The Ophthalmic Pharmaceuticals portfolio includes Ilevro ophthalmic suspension for the treatment of pain and inflammation associated with cataract surgery; Simbrinza suspension to lower intraocular pressure as a fixed-dose combination; Travatan Z, Izba and DuoTrav, each ophthalmic solutions for the treatment of elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension; Vigamox ophthalmic solution for bacterial conjunctivitis; Pataday ophthalmic solution for ocular itching associated with allergic conjunctivitis; Nevanac ophthalmic suspension for eye pain and inflammation following cataract surgery, and to reduce the risk of macular edema associated with cataract surgery in diabetic patients; the Systane family of over-the-counter products for dry eye relief; and Jetrea intravitreal injection for treating vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400 microns. Vision Care The Alcon division's Vision Care franchise develops and markets contact lenses and lens care products. The company’s portfolio of silicone hydrogel,


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $86.40 USD -0.25

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $162.78 USD +0.31
Gilead Sciences Inc $106.57 USD +0.21
Johnson & Johnson $102.04 USD -0.73
Nestle SA SFr.74.80 CHF -0.95
Pfizer Inc $31.97 USD +0.64
View Industry Companies

Industry Analysis


Industry Average

Valuation NVS Industry Range
Price/Earnings 25.4x
Price/Sales 4.1x
Price/Book 2.7x
Price/Cash Flow 11.4x
TEV/Sales 3.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NOVARTIS AG-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at